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Abstract
Background
Reactive oxygen species (ROS) are largely considered to be pathogenic to normal endothe-
lial function in disease states such as sepsis. We hypothesized that Angiopoietin-1 (Angpt-
1), an endogenous agonist of the endothelial-specific receptor, Tie-2, promotes barrier de-
fense by activating NADPH oxidase (NOX) signaling.
Methods and Findings
Using primary humanmicrovascular endothelial cells (HMVECs), we found that Angpt-1 stim-
ulation induces phosphorylation of p47phox and a brief oxidative burst that is lost when
chemical inhibitors of NOX activity or siRNA against the NOX component p47phox were ap-
plied. As a result, there was attenuated ROS activity, disrupted junctional contacts, enhanced
actin stress fiber accumulation, and induced gap formation between confluent HMVECs. All
of these changes were associated with weakened barrier function. The ability of Angpt-1 to
prevent identical changes induced by inflammatory permeability mediators, thrombin and li-
popolysaccharides (LPS), was abrogated by p47phox knockdown. P47phox was required for
Angpt-1 to activate Rac1 and inhibit mediator-induced activation of the small GTPase RhoA.
Finally, Angpt-1 gene transfer prevented vascular leakage in wildtype mice exposed to sys-
temically administered LPS, but not in p47phox knock out (p47−/−) littermates.
Conclusions
These results suggest an essential role for NOX signaling in Angpt-1-mediated endothelial
barrier defense against mediators of systemic inflammation. More broadly, oxidants gener-
ated for signal transduction may have a barrier-promoting role in vascular endothelium.
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INTRODUCTION
Angiopoietin-1 (Angpt-1) stimulates Tie-2, a receptor tyrosine kinase whose expression is
largely limited to the endothelium. Knockout mice for either ligand or receptor are embryoni-
cally lethal with a gross defect in vascular stabilization during developmental angiogenesis
[1,2]. Based on data demonstrating persistent Tie-2 activation in adult blood vessels [3],
Angpt-1 was subsequently shown to promote barrier defense in the mature, non-angiogenic
vasculature against VEGF, serotonin, and mustard oil [4,5]. Using sepsis as a model condition
for systemic vascular leakage, we have shown that Angpt-1 gene transfer or an Angpt-1-mimet-
ic peptide prevents vascular leakage and improves survival in a Tie-2-dependent fashion [6,7].
Given the potential for therapeutic translation and the broad-ranging barrier defense effect
against these diverse permeability mediators, insights into Angpt-1’s mechanism of action
are critical.
Angpt-1 promotes endothelial cell (EC) spreading and enhanced cell-cell contacts by coor-
dinately signaling Rho family GTPases that, in turn, regulate cytoskeletal and junctional effec-
tor proteins. Angpt-1 stimulates Rac1, which then inhibits RhoA [8–10]. When the ability of
Angpt-1 to suppress RhoA is artificially blocked, Angpt-1 can no longer counteract in vitro
barrier dysfunction or in vivo vascular leakage mediated by the classic RhoA activator lipopoly-
saccharides (LPS) [9]. The importance of endothelial RhoA activation for LPS-induced leakage
in vivo has been further illustrated by an independent work showing that inhibition of the
RhoA effector protein, endothelial cell myosin light chain kinase (EC-MLCK), also counteracts
vascular leakage in mice following LPS challenge [11]. Therefore, addressing how Angpt-1 in-
hibits RhoA is critical to understanding its barrier defense mechanism.
The NADPH oxidase complex is comprised of membrane-bound flavocytochrome b558
(composed of p22phox and gp91phox/NOX2) and cytosolic regulatory subunits ofp47phox,
p40phox, p67phox and Rac1 or Rac2 [12]. The precise role of Angpt-1 in generation of endo-
thelial ROS via NADPH oxidase and thereby Rac1 activation/RhoA inhibition is not clearly es-
tablished. It is believed that phosphorylation of p47phox is required for receptor-mediated
NOX2 activation and intercellular ROS generation[12]. We hypothesized that Angpt-1 medi-
ates p47-dependent NADPH oxidase (NOX) activity which may contribute to Angpt-1-medi-
ated RhoA suppression and barrier defense in microvascular endothelium. Previous work has
suggested a role for NOX-derived oxidants in the angiogenic actions of Angpt-1 [11,13,14], but
in vascular leakage related to systemic inflammation, oxidants are widely considered to be me-
diators of leak rather than signaling components of the barrier defense response [15].
To test this hypothesis, we first confirmed that Angpt-1 application to HMVECs induced a
NOX-dependent oxidative burst. Next, we found that the chemical inhibition of NOX2 and
p47phox component was sufficient to block the Angpt-1-mediated oxidative burst. Finally, we
evaluated endothelial architecture, barrier function, and in vivo vascular leakage in a series of
experiments using Angpt-1, LPS, thrombin, NOX-2 inhibitor and genetic manipulation of
p47phox. Our results suggest that a NOX-dependent oxidative burst not only follows Angpt-1
stimulation, but is critical to the suppression of RhoA and barrier defense against inflammatory
permeability mediators.
MATERIALS ANDMETHODS
Antibodies and Reagents
Antibodies used for immunoblotting and immunocyto/-histochemistry were purchased from the
following manufacturers: p47phox and actin (C-11) from Santa Cruz (Santa Cruz, CA), phos-
pho-p47s304 from Abcam (Cambridge, MA), Tie2 fromMillipore (Danvers,MA), VE-cadherin
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from BD Bioscience (San Jose, CA), and anti Rac1 and anti RhoA from Cytoskeleton (Denver,
CO).CM-H2DCFDA, Phalloidin, DAPI (40,6-diamidino-2-phenylindole),and fluorophore- or
horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Life Tech-
nologies (Carlsbad, CA).Thrombin was procured from Calbiochem (San Diego, CA). LPS (O111:
B4)/LBP/CD14, Phospho-Tie2Y992, recombinant Angpt-1 were procured from R&D Biosystems
(Rochester, MN). The adenovirus expressing Angpt-1 and GFP were obtained from Qbiogene
Inc (Carlsbad, CA).Other reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture and Reagents
Passage 4–6 human microvascular endothelial cells (HMVECs) from dermis (Lonza) were cul-
tured on collagen I (Advanced BioMatrix Inc.) in EBM-2 media (Lonza) supplemented with
5% FBS and growth factors. Apocynin (Apo), siRNAs, and Lipofectin were purchased from
Life Technologies. Hyper-3 (pC1-HyPer-3) was obtained from Addgene (Cambridge, MA)[16]
and was transfected using X-fect transfection kit from Clontech (Mountain View, CA) as per
manufacturer's instruction.
Mouse Study
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The Institutional An-
imal Care and Use Committee at Beth Israel Deaconess Medical Center (Animal Welfare As-
surance Number: A3153-01) approved this protocol. Male p47phox knockout mice and their
wildtype littermates on C57BL6/J background were purchased form Jackson Labs (Bar Harbor,
Maine).
Reactive Oxygen Species (ROS) measurement
DCFDA studies. Intracellular ROS were determined based on the principle of oxidative
conversion of cell permeable chloromethyl-20,70-dichlorodihydrofluorescein diacetate to fluo-
rescent dichlorofluorescein (DCF) as mentioned elsewhere[13]. Briefly, confluent HMVECs
(P5) were serum starved with 1% FBS overnight, incubated with 10 μMCM-H2DCFDA in PBS
for 30 minutes before stimulation with Angpt-1 (300ng/ml). DCF fluorescence was measured
over the whole field of vision using a Zeiss fluorescence microscope connected to an imaging
system. Ten high-power images per experiment were obtained for later planimetric quantifica-
tion using a single threshold value for all images in Adobe Photoshop as described previously
[17].
Live cell imaging to measure ROS. To overcome the non-specificity of the chemical
probes, Hyper-3, a plasmid based biosensor can efficiently measure the generation of intercellular
ROS in real time [16].Fifty to sixty percent confluent of HMVECs were grown in Lab-TekII cham-
bered plates (Thermo Scientific, Rochester, NY) and were transfected with Hyper-3 plasmid using
X-fect (Clontech) as per the manufacturer's protocol. After 48 hours of transfection, cells were
serum starved for 2 hours before addition of chemicals such as VAS2870 (endothelial NOX2 and
NOX4 inhibitor)[18] and Apo. Thirty minutes after the addition of the chemicals cells were treat-
ed with Angpt-1 and H2O2. The images were taken in Zeiss LSM510META live cell confocal mi-
croscope confocal system at x20 with as described earlier with single wave length monitoring [19].
Of note, all images were obtained with the same laser power, gain, and offset conditions. The in-
tensity of the cells before and after treatment was measured by ImageJ (NIH, Baltimore, MD) and
the fold change in the intensity of the same cell was considered for calculation.
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RNA interference
The siRNA-mediated interference in HMVECs were achieved as described previously with small
modifications[8]. Briefly, HMVECs were grown to 70–80% confluence in 6-cm plates and trans-
fected with 5, 20nMp47phoxsiRNA against p47phox (5-GGUCAUUCACAAGCUCCUGtt-3,
Ambion, Austin, TX), or scrambled siRNA(Scramsi) in Opti-MEM containing 10μg/ml Lipofec-
tin as per manufacturer's protocol (Life Technologies, Carlsbad, CA). Cells were harvested after
48 hours of transfection.For ECIS experiments we used HyPerFect (Qiagen, Valencia, CA) with
a fast forward protocol recommended by the manufacturer.
Immunocytochemistry
HMVECs were grown to confluence on glass cover-slips coated with collagen type I. After star-
vation, the cells were treated with LBP (100ng/mL) and CD14 (10ng/mL) for 30 minutes before
treating with LPS (100ng/ml) in presence or absence of Angpt-1(300ng/ml) for another 30
minutes. Cells were fixed for 10 minutes with 2.5% para-formaldehyde and permeabilized for
5 minutes with 0.2% Triton X-100 in PBS. Cells were blocked overnight at 4°C with a blocking
buffer (1% BSA, 0.1% Triton X-100, 0.1% sodium azide), then incubated for 12 hours with pri-
mary antibody, serial washes in PBS, then a 60 minute incubation with secondary Alexa-fluor-
antibody and phalloidin. The coverslips were mounted by using ProLong Gold/DAPI. All
images were taken by a Zeiss LSM510 META confocal system at X63. Of note, all images were
obtained with the same laser power, gain, and offset conditions.
RhoA/Rac1GTPmeasurements
Rho-GTP was measured in 100% confluent HMVECs. Cells were treated with Apo (650 uM),
Angpt-1 (300 ng/mL), and with or without Thrombin (1 U/ml) for 15 minutes to activate
RhoA. Protein lysates were collected, and activated GTP-bound RhoA was analyzed with a
GLISA activation assay kit (Cytoskeleton, Denver, CO) according to the manufacturer's
instructions.
Western Blot Analysis
Cells or organ lysates were prepared by homogenization in ice-cold RIPA buffer (Boston Bio-
Products, Boston, MA) supplemented with protease inhibitors (Roche Diagnostics, Indianapo-
lis, IN), 1 mM EDTA, 1 mMNa3VO4, and 1 mMNaF. Lysates were sonicated and centrifuged
at 8,000 g for 10 minutes at 4°C, and supernatants were collected. Electrophoresis, transfer, im-
munoblotting, detection, and image acquisition were performed as previously described
[20,21].
Trans-endothelial electrical resistance
HMVECs were grown to confluence in polycarbonate wells containing evaporated gold micro-
electrodes in series with a large gold counter connected to a phase-sensitive lock-in amplifier as
described previously [22–24]. To silence p47phox we used 20nM of p47phoxsiRNA and Fast
Forward protocol as per manufacturer's direction (Qiagen)[25]. Twenty-four hours after of
transfection, the confluency of cells were evaluated and base line resistance was measured in an
electrical cell-substrate impedance sensing system (ECIS-1600) (Applied Biophysics, Troy,
NY) as described before [6,8,26].When the cells reached the resistance more than 1500 ohm
generally 36–48 hours of post transfection, cells were treated with Angpt-1, Thrombin, LPS,
LBP, and CD14.
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Measurements of TER were performed in real-time and values from each microelectrode
were pooled at discrete time points and either plotted versus time as the mean ± SEM or re-
ported as bar graphs at the time-point of maximal response to a given stimulus as described
elsewhere in detail [27].
Mouse Evans blue (EB) permeability assay in lungs
To measure the LPS induced vascular leak we injected LPS (15mg/kg body weight) to 8–12
week-old male mice. Viral particles (2 × 1010) of Ad-Angpt-1 or control adenovirus (Ad-
CMV-GFP) were administered by tail vein 48 hours before LPS administration. Sixteen hours
after LPS injection, animals were deeply anesthetized with inhaled isoflurane and EB dye was
injected intravenously as previously described [6,28,29]. The following formula was used to
correct the optical densities (shown as E(wavelength)) for contamination with heme pigments:
E620(corrected) = E620(raw)−(1.426 x E740(raw) + 0.03)
Statistical analysis
Data are presented as mean ± SEM unless otherwise noted. For statistical comparisons between
two groups, we used unpaired, two-tailed Student's t-test. For comparisons of 3 or more groups,
we used One-way analysis of variance (ANOVA) with Bonferroni's multiple comparison post
hoc test. Differences of p< 0.05 were considered significant. The results were analyzed in
GraphPadPrism5.0 (San Diego, CA).
RESULTS
Angpt-1 induces a p47phox-dependent oxidative burst in endothelium
Given the role of NOXs in regulating GTPases and our previous findings in support of a GTPase
mechanism of Angpt-1 barrier defense [8,9], we hypothesized that NOXs may be involved in
Angpt-1-mediated barrier defense. We focused on p47phox based upon a large body of literature
describing its functions in the endothelium (summarized in [30]. We first validated a siRNA
against p47phox in HMVECs (Fig. 1A). We then used the cell-permeable reactive oxygen species
detector dye, DCFDA, to follow the oxidative burst induced by Angpt-1 as previously reported
[11,13,14]. We found that the chemical NOX inhibitor, Apo, or p47phox siRNA was sufficient to
abrogate this burst (Fig. 1B,C). To overcome the non-specificity of the chemical redox probe, we
used genetically defined redox probe-plasmid, Hyper-3[16,19].Using time-lapse imaging, we ob-
served that H2O2 as well as Angpt-1 generate intracellular ROS (Fig. 1D-G).The effect of Angpt-
1 was significantly reducedwhen Hyper-3 transfected cellswere pretreated with VAS2870, Apo,
or p47phox siRNA (Fig. 1H).We also explored whether Angpt-1 phosphorylates p47phox and
may alter the localization of p47phox from cytosol to membrane to augment ROS production.
We found that Angpt-1 induces phosphorylation of p47phox at serine-304, an important regula-
tory site for p47phox (S1 Fig.).
Angpt-1 requires NOX activity to inhibit thrombin-induced RhoA
activation
We have previously described that Angpt-1 activates Rac1, which in turn, inhibits RhoA. this
mechanism is required for Angpt-1-mediated barrier defense [8,9]. We used a canonical stimu-
lator of RhoA, thrombin, to test whether NOX activity was necessary for Angpt-1 to inhibit
thrombin-induced RhoA activation (measured as the GTP-bound form of RhoA). Our results
showed that Angpt-1 inhibits both basal and thrombin-induced RhoA activation (Fig. 2). In
unstimulated HMVECs, Apo induced RhoA activation, suggesting basal NOX activity is unable
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
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Fig 1. Angpt-1 induces a p47phox-dependent oxidative burst in endothelium. (A) Titration and validation of p47phox siRNA delivery into HMVECs. (B)
Example epifluorescence (excitation 495 nm: emission 520 nm) and corresponding bright field images of individual HMVECs loaded with CM-H2DCFDA,
pre-treated with Apo (650 μM), control siRNA, or p47phox siRNA, and then treated with Angpt-1 (300 ng/ml). Images shown were taken 5 minutes after
Angpt-1 addition. Scale bar 10 μm. (C) Planimetric quantification of CM-H2DCFDA fluorescence from above conditions (n = 3–5 experiments per condition).
***p<0.001 compared to p47phox siRNA+Angpt-1. (D-G) Cells transfected with Hyper-3 for 48 hours, underwent serum starvation for 2 hours, were treated
with 10 μMH2O2 or Angpt-1 (300 ng/ml), and changes in fluorescence intensity were measured by live cell imaging microscopy. Representative images after
2 minutes of H2O2 (D-E) and 5 minutes with Angpt-1 (F-G) are shown. (H) Hyper-3 transfected HMVECs were, treated with chemicals (Apo and VAS 2870),
siRNA p47phox or Tie2-Fc (500 ng/ml) before addition of Angpt-1 (300 ng/ml). Results were analyzed by one-way ANOVA followed by post-hoc corrections
for multiple comparisons. ***p<0.001,***p<0.01 relative to Angpt-1 alone.
doi:10.1371/journal.pone.0119577.g001
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to prevent RhoA activity; therefore, Angpt-1 could no longer inhibit RhoA in this situation.
These results demonstrate the reliance of Angpt-1 on NOXs to prevent mediator-induced
RhoA activation.
p47phox enables Angpt-1 to counteract cellular structural
rearrangements induced by thrombin
The balance of intracellular GTPases dictates the cytoskeletal architecture of endothelial cells,
which in turn may regulate permeability [31]. We predicted that actin stress fibers and paracel-
lular gaps induced by thrombin and prevented by Angpt-1 would involve p47phox. To test
Fig 2. Angpt-1 requires NOX activity to inhibit thrombin-induced RhoA activation.Confluent HMVECs were treated with vehicle (NT), Angpt-1 (300 ng/ml),
Apo (650 μM), and/or thrombin (1 U/ml). Cells were lysed in the manufacturer-provided buffer 15minutes after treatments for RhoAG-LISA, a pulldown method
for RhoA-GTP detection. The results were then normalized to total RhoA, as determined by densitometry of Western blots (n = 4–6 experiments per condition).
*p< 0.05.
doi:10.1371/journal.pone.0119577.g002
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this, we used control or p47phox siRNA on HMVECs. While p47phox knockdown alone had
no discernible effect on stress fibers or gaps (data not shown), the ability of Angpt-1 to counter-
act the cytoskeletal and junctional effects of thrombin was lost upon p47phox reduction
(Fig. 3A-P).
P47phox is required for Angpt-1-mediated barrier defense against
thrombin and LPS
The electrical resistance of a confluent cellular monolayer provides a sensitive measure of real-
time changes in monolayer permeability. Thrombin has a well-described permeability effect on
ECs in this assay that relies on activated RhoA[32]. Gram-negative lipopolysaccharide (LPS) is
a medically important mediator of vascular leakage in severe infectious syndromes[33]. LPS in-
duces endothelial barrier dysfunction that is both RhoA-dependent and preventable by Angpt-
1 application [6,9]. To explore whether Angpt-1-mediated barrier defense against LPS also re-
quires NOX signaling, we first studied the HMVEC cytoskeleton and junctions using Apo.
The ability of Angpt-1 to prevent LPS-induced structural changes was lost upon Apo addition
(S2 Fig.).
Based on the ability of Angpt-1 to counteract thrombin-induced RhoA activation in a
p47phox-dependent fashion (Fig. 3), we asked whether Angpt-1 could counteract thrombin-
induced barrier dysfunction, and if so, whether this form of barrier defense required p47phox.
Compared to control siRNA, p47phox silencing had no effect on basal barrier function without
the presence of thrombin (Fig. 4A, left of thrombin arrow). Upon addition of thrombin,
p47phox-siRNA HMVECs responded with a greater fall in resistance than control-siRNA
HMVECs. Angpt-1 substantially attenuated the thrombin-induced fall in resistance of control
siRNA-treated HMVECs. This protective effect was lost in p47phox-siRNA HMVECs
(Fig. 4A,B). These results show that reduction of p47phox exacerbates barrier dysfunction in-
duced by the canonical RhoA activator, thrombin, and that Angpt-1’s barrier-protective effect
against thrombin relies on intact p47phox expression.
In a previous study, we observed that Tie-2 stimulation with a synthetic Angpt-1-peptide
mimetic counteracted the LPS-induced fall in electrical resistance of confluent HMVECs [6].
We therefore used the same assay to test the role of p47phox. Compared to control siRNA,
knockdown of p47phox reduced the resistance of confluent HMVECs treated with LPS+Angpt-1
(Fig. 4C). Of note, HMVECmonolayers treated with LPS alone showed a 20% drop in resistance,
statistically indistinguishable from LPS+Angpt-1+p47phox siRNA (data not shown). Together
with the thrombin studies in HMVECs, these data provide evidence that Angpt-1-mediated bar-
rier defense against RhoA-dependent mediators of permeability requires p47phox.
Angpt-1 mediated barrier defense in acute systemic inflammation
requires p47phox
We and others have previously shown that Angpt-1 (or mimetics thereof) counteract critical
manifestations of sepsis in experimental rodent models [6,7,9,34–37]. LPS injection in mice
induces systemic inflammation that mimics features of the early cytokine storm in sepsis, such
as severe vascular leakage. To evaluate the significance of the proposed p47phox-dependent
barrier defense mechanism of Angpt-1 in vivo, we administered LPS with or without Angpt-1
gene transfer by adenovirus in p47−/−mice and their wildtype littermates. LPS induced compa-
rable vascular leakage in p47−/− and wildtype mice. Inwildtype mice, Angpt-1 gene transfer
prevented the LPS-induced increase in lung permeability (Fig. 5A). However, the anti-perme-
ability effect of Angpt-1 against LPS was lost in p47−/−mice. In addition, LPS functioned as a
“double-edged sword” by decreasing the activation of pTie2 and reducing the level of total Tie2
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
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protein without affecting the total protein level of Rac1 (S3 Fig.). As previously shown [9,35],
LPS-induced cellular infiltration of the lungs was also attenuated by Angpt-1, but again, dele-
tion of p47phox abrogated this protective effect (Fig. 5B-D).
Fig 3. p47phox enables Angpt-1 to counteract cellular structural rearrangements induced by thrombin. (A-H) Confluent HMVECs were treated with
control siRNA, thrombin (1 U/ml, A-D), or the combination of Angpt-1 (300 ng/ml) plus thrombin (E-H). After 15 minutes, cells were fixed, permeabilized, and
stained for nuclei (blue, DAPI), VE-cadherin (green), or F-actin (red). White arrows indicate paracellular gaps. (I-P) Repeat of the above experiments,
replacing control siRNA with p47phox siRNA. Representative of n = 3–4 experiments per condition. Scale bar 10 μm.
doi:10.1371/journal.pone.0119577.g003
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DISCUSSION
Our results show that Angiopoietin-1 counteracts endothelial barrier dysfunction induced
by canonical inflammatory mediators, LPS and thrombin, by signaling through the NOX
subunit p47phox. To arrive at this conclusion, we used chemical and genetic manipulations
of Angpt-1-induced NOX signaling with a combination of three techniques to assess barrier
modulation—immunocytochemistry of cytoskeletal and junctional proteins, the highly sensi-
tive electrical resistance assay, and adult mice in which vascular leakage was provoked by LPS
challenge. The results suggest that oxidant production is a critical component of the signal
transduction cascade that enables Angpt-1 to promote endothelial barrier defense.
Previous work on the role of oxidants in endothelial barrier function has generally proposed
that these molecules are mediators of increased vascular permeability, particularly since reac-
tive oxygen species are generated during ischemia-reperfusion injury and by activated neutro-
phils (reviewed in [15,38]). However, experimental systems for studying oxidant-induced
endothelial barrier dysfunction, such as application of H2O2 to EC monolayers, may not be an
appropriate comparison for interpreting the effects we observed following Angpt-1 application.
First, the oxidative burst we observed is brief compared to the sustained exposure to H2O2 nec-
essary to provoke barrier dysfunction. Second, and perhaps more importantly, the production
Fig 4. p47phox is required for Angpt-1-mediated barrier defense against thrombin. (A) Transendothelial resistance assay (TER) of confluent HMVECs
treated with thrombin (1 U/ml), with p47phox or control siRNA, and with and without Angpt-1 (300 ng/ml). n = 4 experiments per condition. To enable
comparisons between conditions, the baseline absolute resistance of each well was used to normalize subsequent readings for the respective well. (B) Data
from (A) quantified as the change in normalized resistance 30 minutes after thrombin addition. ***p<0.001. (C) Transendothelial resistance assay (TER) of
control- vs. p47phox-siRNA-treated HMVECs to which LPS (10 ng/ml) and Angpt-1 (300 ng/ml) were applied. The change was recorded 1 hour after LPS and
Angpt-1 addition (n = 3 experiments per condition). ***p< 0.001, n = 4 experiments per condition.
doi:10.1371/journal.pone.0119577.g004
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of a superoxide following Angpt-1 is likely restricted to signaling complexes assembled around
Tie2 and NOXs. Although speculative, compartmentalization of the oxidative burst may also
help explain how NOX activity is also downstream of endothelial pathways such as VEGF that
are known to enhance permeability [39,40].
Several studies have reported that Angpt-1 stimulates NOX activity, implicating this pathway
in the migration of ECs [11,13,14]. None, however, have asked whether NOX activity also con-
tributes to barrier defense of confluent ECs. One potential explanation for these two apparently
discrepant phenotypes observed in cell culture may relate to the experimental conditions. In
sparsely cultured cells, activation of Rac1 induces dorsal ruffles and, in gradient settings, activat-
ed Rac1 accumulates at the leading edge of the migrating cell where it promotes cell spreading
through lamellipodia [41]. By contrast, there is no “room” for migration among confluent cells.
Nonpolar Rac1 activation in this setting may promote spreading of cells in all directions,
Fig 5. Angpt-1 mediated barrier defense in acute systemic inflammation requires p47phox. (A) Spectrophotometric quantification at 620 nm of
intravenously injected Evans blue dye extravasation into the lungs of wildtype littermates (p47+/+) and p47phox KOmice (p47−/−) 16 hours after LPS (15 mg/kg
IP) with prior control adenovirus (control) or Angpt-1 adenovirus (1 x 109pfu/mouse) gene transfer. (B-D) Lung photomicrographs from above conditions
(representative of n = 3–5 mice per condition). Scale bar 50 μm.
doi:10.1371/journal.pone.0119577.g005
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resulting in enhanced physical overlap between adjacent cells [31]. Such a mechanism could ac-
count for the enhanced barrier function that follows Rac1 stimulation in confluent settings,
while also explaining Rac1-dependent migration in sparse settings. Studies also show the impor-
tance of Rac1 and p47phox localization—for example, membrane-to-cytosol translocation may
be responsible for enhanced barrier integrity [42].
Further questions are suggested by our results. First, is NOX activation a general feature of
endothelial barrier defense regardless of the upstream pathway? Our data with chemical inhibi-
tion of NOX activity supports this hypothesis, but more experiments are needed. Second, glob-
al knockout mice for p47phox have impaired neutrophil function; therefore, an endothelial-
specific p47phox deletion would be even more informative about the role of NOX signaling in
endothelium in vivo. However, we should note that KO mice and their wildtype littermates
had equivalent permeability responses to LPS. Furthermore, the highly restricted expression of
Angpt-1’s receptor, Tie2, to endothelium confers additional cellular specificity to the in vivo re-
sults. Nonetheless, Angpt-1 could have acted on putative non-Tie-2 receptors [43], and extra-
endothelial effects of p47phox deletion could still have factored into the observed permeability
results. [8,9]. We also observed that Angpt-1 phosphorylates p47phox at S-304, one of the im-
portant sites of p47phox phosphorylation (Fig. 2A,B) that is not completely reversed by treat-
ing the cells with NOX inhibitor [44]. Finally, compartmentalization of the NOX oxidative
burst in ECs merits further characterization.
In summary, the present work identifies p47phox-dependent NOX activity as a critical com-
ponent of Angpt-1-mediated endothelial barrier defense against classic inflammatory perme-
ability factors. These results advance our understanding of the wide-ranging barrier defense
signaled by Angpt-1 and, more broadly, suggest that oxidants within ECs may have barrier-
promoting properties.
Supporting Information
S1 Fig. Angpt-1 induces p47phox phosphorylation in endothelium. (A) Confluent HMVECs
were serum-starved overnight, then treated with VAS2870 (10 μM) for 30 minutes before addition
of Angpt-1 for 15 minutes. Protein lysates were resolved byWestern and probed for phospho-
p47phoxs304, total p47phox. Equal loading was confirmed by detecting total Rac1. (B)Densitome-
try analysis showing the ratio of phospho p47phoxS304/total p47phox. p< 0.05;p< 0.01, n = 3
per condition).
(TIF)
S2 Fig. The role of p47phox in Angpt-1-mediated barrier defense extends to LPS. (A-D)
Confluent HMVECs were treated with Apo (650 μM) 30 minutes prior to LPS (10 ng/ml) with
or without Angpt-1 (300 ng/ml) for 30 minutes and then stained for VE-cadherin (green) and
F-actin (red). White arrows indicate paracellular gaps. Representative of n = 3 experiments per
condition. Scale bar 10 μm.
(TIF)
S3 Fig. Stable Tie2-signaling in p47phox−/−mice. Lung lysates of p47phox−/−mice after
transduction with Ad-Angpt-1 or Ad-GFP. The levels of pTie2 and pTie2 were evaluated by
Western analysis.
(TIF)
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
PLOS ONE | DOI:10.1371/journal.pone.0119577 March 11, 2015 12 / 15
Author Contributions
Conceived and designed the experiments: AM SD CCG SMP. Performed the experiments: AM
SD CCG KEM JTH. Analyzed the data: AM SD CCG KEM SMP. Contributed reagents/materi-
als/analysis tools: AM CCG. Wrote the paper: KEM CCG SMP.
REFERENCES
1. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, et al. (1994) Dominant-negative and tar-
geted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogen-
esis of the embryo. Genes Dev 8: 1897–1909. PMID: 7958865
2. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, et al. (1996) Requisite role of angiopoietin-
1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180. PMID: 8980224
3. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, et al. (1997) Tie2 expression and phos-
phorylation in angiogenic and quiescent adult tissues. Circ Res 81: 567–574. PMID: 9314838
4. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, et al. (2000) Angiopoietin-1 protects the adult vascula-
ture against plasma leakage. Nat Med 6: 460–463. PMID: 10742156
5. Thurston G, Suri C, Smith K, McClain J, Sato TN, et al. (1999) Leakage-resistant blood vessels in mice
transgenically overexpressing angiopoietin-1. Science 286: 2511–2514. PMID: 10617467
6. David S, Ghosh CC, Kumpers P, Shushakova N, Van Slyke P, et al. (2011) Effects of a synthetic PEG-
ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Phy-
siol 300: L851–862. doi: 10.1152/ajplung.00459.2010 PMID: 21421750
7. Kumpers P, Gueler F, David S, Van Slyke P, Dumont DJ, et al. (2011) The synthetic Tie2 agonist pep-
tide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis.
Crit Care 15: R261. PMID: 22040774
8. David S, Ghosh CC, Mukherjee A, Parikh SM (2011) Angiopoietin-1 Requires IQ Domain GTPase-Acti-
vating Protein 1 to Activate Rac1 and Promote Endothelial Barrier Defense. Arterioscler Thromb Vasc
Biol.
9. Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, et al. (2007) Angiopoietin-1 requires p190
RhoGAP to protect against vascular leakage in vivo. J Biol Chem 282: 23910–23918. PMID: 17562701
10. Cascone I, Audero E, Giraudo E, Napione L, Maniero F, et al. (2003) Tie-2-dependent activation of
RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood 102: 2482–
2490. PMID: 12816861
11. Wainwright MS, Rossi J, Schavocky J, Crawford S, Steinhorn D, et al. (2003) Protein kinase involved in
lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treat-
ment. Proc Natl Acad Sci U S A 100: 6233–6238. PMID: 12730364
12. Babior BM (1999) NADPH oxidase: an update. Blood 93: 1464–1476. PMID: 10029572
13. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, et al. (2005) Roles of reactive oxygen species
in angiopoietin-1/tie-2 receptor signaling. FASEB J 19: 1728–1730. PMID: 16049136
14. Kim YM, Kim KE, Koh GY, Ho YS, Lee KJ (2006) Hydrogen peroxide produced by angiopoietin-1 medi-
ates angiogenesis. Cancer Res 66: 6167–6174. PMID: 16778190
15. Mehta D, Malik AB (2006) Signaling mechanisms regulating endothelial permeability. Physiol Rev 86:
279–367. PMID: 16371600
16. Bilan DS, Pase L, Joosen L, Gorokhovatsky AY, Ermakova YG, et al. HyPer-3: a genetically encoded H
(2)O(2) probe with improved performance for ratiometric and fluorescence lifetime imaging. ACS Chem
Biol 8: 535–542. doi: 10.1021/cb300625g PMID: 23256573
17. David S, Mukherjee A, Yano M, Ghosh CC, Khankin EV, et al. (2012) Angiopoietin-2 may contribute to
multi-organ dysfunction and adverse outcomes in sepsis. Crit Care Med (accepted).
18. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, et al. (2006) Novel Nox inhibitor of oxLDL-in-
duced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun
344: 200–205. PMID: 16603125
19. Mishina NM, Markvicheva KN, Bilan DS, Matlashov ME, Shirmanova MV, et al. Visualization of intracel-
lular hydrogen peroxide with HyPer, a genetically encoded fluorescent probe. Methods Enzymol 526:
45–59. doi: 10.1016/B978-0-12-405883-5.00003-X PMID: 23791093
20. Tran M, Tam D, Bardia A, Bhasin M, Rowe GC, et al. (2011) PGC-1alpha promotes recovery after
acute kidney injury during systemic inflammation in mice. J Clin Invest 121: 4003–4014. doi: 10.1172/
JCI58662 PMID: 21881206
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
PLOS ONE | DOI:10.1371/journal.pone.0119577 March 11, 2015 13 / 15
21. Ghosh CC, Mukherjee A, David S, Knaus UG, Stearns-Kurosawa DJ, et al. Impaired function of the Tie-
2 receptor contributes to vascular leakage and lethality in anthrax. Proc Natl Acad Sci U S A 109:
10024–10029. doi: 10.1073/pnas.1120755109 PMID: 22665799
22. Giaever I, Keese CR (1993) A morphological biosensor for mammalian cells. Nature 366: 591–592.
PMID: 8255299
23. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR, Giaever I (1992) Electrical method for detection of
endothelial cell shape change in real time: assessment of endothelial barrier function. Proc Natl Acad
Sci U S A 89: 7919–7923. PMID: 1518814
24. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, et al. (2001) Sphingosine 1-phosphate promotes
endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689–
701. PMID: 11544274
25. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, et al. (2004) Vascular endothelial growth factor acti-
vates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 24: 294–300.
PMID: 14656735
26. Xie Z, Ghosh CC, Parikh SM, Druey KM (2014) Mechanistic classification of the systemic capillary leak
syndrome: clarkson disease. Am J Respir Crit Care Med 189: 1145–1147. doi: 10.1164/rccm.201310-
1746LE PMID: 24787070
27. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, et al. (2001) Sphingosine 1-phosphate promotes
endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of clinical
investigation 108: 689–701. PMID: 11544274
28. David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, et al. (2012) Angiopoietin-2 may contribute to
multiple organ dysfunction and death in sepsis. Crit Care Med 40: 3034–3041. doi: 10.1097/CCM.
0b013e31825fdc31 PMID: 22890252
29. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, et al. (2006) Excess circulating angiopoietin-
2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 3: e46. PMID: 16417407
30. Ushio-Fukai M (2006) Localizing NADPH oxidase-derived ROS. Sci STKE 2006: re8.
31. Dudek SM, Garcia JG (2001) Cytoskeletal regulation of pulmonary vascular permeability. J Appl Phy-
siol 91: 1487–1500. PMID: 11568129
32. van Nieuw Amerongen GP, Draijer R, Vermeer MA, van Hinsbergh VW (1998) Transient and prolonged
increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calci-
um, and RhoA. Circ Res 83: 1115–1123. PMID: 9831706
33. Russell JA (2006) Management of sepsis. N Engl J Med 355: 1699–1713. PMID: 17050894
34. David S, Park JK, Meurs M, Zijlstra JG, Koenecke C, et al. (2011) Acute administration of recombinant
Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sep-
sis. Cytokine 55: 251–259. doi: 10.1016/j.cyto.2011.04.005 PMID: 21531574
35. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C (2005) Protective role of
angiopoietin-1 in endotoxic shock. Circulation 111: 97–105. PMID: 15611372
36. Kim DH, Jung YJ, Lee AS, Lee S, Kang KP, et al. (2009) COMP-angiopoietin-1 decreases lipopolysac-
charide-induced acute kidney injury. Kidney Int 76: 1180–1191. doi: 10.1038/ki.2009.387 PMID:
19812542
37. Hwang JA, Lee EH, Lee SD, Park JB, Jeon BH, et al. (2009) COMP-Ang1 ameliorates leukocyte adhe-
sion and reinforces endothelial tight junctions during endotoxemia. Biochem Biophys Res Commun
381: 592–596. doi: 10.1016/j.bbrc.2009.02.096 PMID: 19245790
38. Kunsch C, Medford RM (1999) Oxidative stress as a regulator of gene expression in the vasculature.
Circ Res 85: 753–766. PMID: 10521248
39. Abid MR, Schoots IG, Spokes KC, Wu SQ, Mawhinney C, et al. (2004) Vascular endothelial growth fac-
tor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regula-
tion of forkhead and IkappaB/NF-kappaB. J Biol Chem 279: 44030–44038. PMID: 15308628
40. Ushio-Fukai M, Alexander RW (2004) Reactive oxygen species as mediators of angiogenesis signal-
ing: role of NAD(P)H oxidase. Mol Cell Biochem 264: 85–97. PMID: 15544038
41. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac
regulates growth factor-induced membrane ruffling. Cell 70: 401–410. PMID: 1643658
42. ChenW, Pendyala S, Natarajan V, Garcia JG, Jacobson JR (2008) Endothelial cell barrier protection
by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol
295: L575–583. doi: 10.1152/ajplung.00428.2007 PMID: 18658277
43. Ahmad S, Cudmore MJ, Wang K, Hewett P, Potluri R, et al. (2010) Angiopoietin-1 induces migration of
monocytes in a tie-2 and integrin-independent manner. Hypertension 56: 477–483. doi: 10.1161/
HYPERTENSIONAHA.110.155556 PMID: 20696992
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
PLOS ONE | DOI:10.1371/journal.pone.0119577 March 11, 2015 14 / 15
44. Hoyal CR, Gutierrez A, Young BM, Catz SD, Lin JH, et al. (2003) Modulation of p47PHOX activity by
site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci U S
A 100: 5130–5135. PMID: 12704229
Angiopoietin-ROS Signaling in Endothelial Barrier Defense
PLOS ONE | DOI:10.1371/journal.pone.0119577 March 11, 2015 15 / 15
